Geron Corp. Stock
Price
Target price
€3.23
€3.23
-5.540%
-0.187
-5.540%
€4.63
23.05.24 / Tradegate
WKN: 902213 / Symbol: GERN / Name: Geron / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Geron Corp. Stock
Heavy losses for Geron Corp. today as the stock fell by -€0.187 (-5.540%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Geron Corp..
With a target price of 4 € there is a positive potential of 23.72% for Geron Corp. compared to the current price of 3.23 €.
So far the community has only identified positive things for Geron Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Geron Corp. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Geron Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Geron Corp. | -5.540% | -9.794% | -3.233% | 10.116% | 64.278% | 182.852% | 137.896% |
Ardelyx Inc. | -10.570% | -13.495% | 3.392% | 89.573% | 7.578% | 9.088% | - |
Evolus Inc | -5.830% | -8.130% | 6.604% | 32.164% | 24.862% | 51.678% | - |
Salarius Pharmaceuticals Inc. | 5.580% | 0.971% | -2.804% | -69.412% | -25.045% | -98.384% | -99.993% |
Comments
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
News
Geron (GERN) Q1 2024 Earnings Call Transcript
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. (NASDAQ: GERN) is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their